Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, are a combined estrogen‑progestogen presented as an oral tablet for oral use. The formulation provides both estrogen and progestogen activity to prevent pregnancy and to replace declining hormones during menopause, and is prescribed for women of reproductive and perimenopausal age.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality through stringent regulatory compliance and reliable cold‑chain‑free distribution. Our network facilitates timely delivery to diverse healthcare settings.

Kliogest, a combined estrogen‑progestogen oral contraceptive, is employed in hormonal regulation pathways to prevent pregnancy and manage menopausal symptoms.

- Contraception: prevents unintended pregnancy by inhibiting ovulation and altering cervical mucus. - Hormone replacement therapy: alleviates menopausal vasomotor symptoms and supports estrogen deficiency. - Menstrual cycle regulation: reduces irregular bleeding and stabilizes endometrial lining.

Kliogest may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of breast tissue. - Spotting or breakthrough bleeding: irregular light bleeding. - Mood changes: irritability or depressive symptoms. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: cerebrovascular accidents. - Myocardial infarction: heart attack risk. - Severe hypertension: sudden high blood pressure. - Hepatic adenoma or cholestatic jaundice: liver abnormalities. - Allergic reactions: anaphylaxis or severe skin rash.

Before prescribing Kliogest, clinicians should evaluate patient risk factors and follow safety guidelines. - Cardiovascular assessment: avoid use in women with uncontrolled hypertension or history of thromboembolism. - Smoking restriction: do not prescribe to smokers of >15 cigarettes per day. - Liver function: assess hepatic disease as metabolism may be impaired. - Blood pressure monitoring: check regularly during treatment. - Pregnancy avoidance: ensure effective contraception; discontinue if pregnancy occurs. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Kliogest can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): reduce contraceptive efficacy. - Anticoagulants (warfarin): may decrease anticoagulant effect, increasing clot risk. - HIV protease inhibitors (ritonavir): may lower hormone levels, compromising contraception. - St. John’s wort: induces metabolism leading to loss of contraceptive protection.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase hormone concentrations, raising side‑effect risk. - Selective serotonin reuptake inhibitors (fluoxetine, sertraline): possible modest increase in plasma levels. - Antibiotics (tetracycline, doxycycline): may slightly reduce effectiveness, advise backup contraception. - Diuretics (hydrochlorothiazide): monitor blood pressure changes.